Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lyophilized intravenous hepatitis B immunoglobulin (pH4) plus lamivudine to prevent post‑transplant HBV reinfection
CTR20140408Phase 3Completed
- Sponsor
- Tonglu Bio-pharmaceutical
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of hepatitis B immune globulin in hepatitis B (HBV), Hepatitis B virus reinfection after liver transplantation (rHBV), sponsored by Tonglu Bio-pharmaceutical. Started Jun 2014; status: completed.
02
Drugs
hepatitis B immune globulin
03
Conditions
hepatitis B (HBV)Hepatitis B virus reinfection after liver transplantation (rHBV)
Beyond the preview
Go deeper on CTR20140408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140408.